Neptune Logitek (544663)
Slow GrowerScore breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹45.01 |
| Market Cap | ₹61.66 Cr |
| P/E Ratio | 8.62 |
| ROCE | 21.62% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | -13.88% |
| Debt/Equity | — |
| Sales Growth | 3.16% |
| Sector | Transport Services |
Strengths
- Low P/E of 8.62, indicating a statistically cheap valuation
- Strong ROCE of 21.62%, showing efficient use of capital
- Positive sales growth of 3.16% in a competitive logistics sector
- Latest quarter net profit of ₹5 crore on ₹125 crore sales suggests operating scale
Concerns
- Profit decline of -13.88% indicates deteriorating earnings momentum
- Piotroski F-Score of 4/9 points to weak financial health
- No dividend yield, so returns depend entirely on share price appreciation
- Insufficient data on debt, book value, and promoter holding creates transparency risk
AI Analysis
When I look at Neptune Logitek, I see a small logistics operator with a market cap of just ₹62 crore and a P/E of 8.62. At first glance, the price looks cheap. But cheap can be a trap if the business is deteriorating. Sales growth is a modest 3.16%, and profits have actually fallen by 13.88%. A PEG ratio of 2.73 tells me the market is not pricing in much future growth, and rightly so. The latest quarter shows sales of ₹125 crore and net profit of ₹5 crore, which seems decent on the surface, but the trailing numbers suggest volatility and pressure on margins. The ROCE of 21.62% is genuinely impressive — it shows the company earns a strong return on capital employed, which is a hallmark of a decent operator. However, I have no data on debt, book value, ROE, or promoter holding. That lack of transparency bothers me. As Graham would say, you cannot judge a business without knowing its balance sheet. The Piotroski F-Score of 4/9 is weak, pointing to financial health concerns. This is not a business with a durable moat; logistics is highly competitive and commoditized. There is no dividend to reward patient holders. The company may be a turnaround candidate, but I see no evidence of a catalyst. I would wait for better data and stronger earnings stability before committing capital.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer